Valuation: Colinz Laboratories Limited

Market Cap 112M 1.18M 1.03M 946K 882K 1.67M 1.7M 11.36M 4.41M 55.1M 4.42M 4.32M 190M P/E 2024
19.5x
P/E 2025 36.8x
Enterprise Value 63.01M 662K 578K 532K 496K 940K 954K 6.38M 2.48M 30.97M 2.48M 2.43M 107M EV / Sales 2024
0.43x
EV / Sales 2025 2.04x
Free-Float
31.44%
Yield 2024 *
-
Yield 2025 -
Jun. 17 Annjana Dugar, Likhitta Dugar and Antariksh Dugar executed of Share Purchase Agreement to acquire an additional 34.56% stake in Colinz Laboratories Limited from Vijaya Mani for INR 43.5 million, CI
Jun. 17 Annjana Dugar, Likhitta Dugar and Antariksh Dugar proposed to acquire an additional 26% stake in Colinz Laboratories Limited for INR 35.4 million. CI
May. 25 Padam Dugar, Annjana Dugar, Likhitta Dugar and Antariksh Dugar acquired 15.01% stake in Colinz Laboratories Limited. CI
Apr. 29 Colinz Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
Jan. 24 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
Jan. 16 Hilsun Foods And Drugs Private Limited signed a letter of intent to acquire Factory Building, Factory Machinery, & Factory Land of Colinz Laboratories Limited for INR 40 million. CI
Nov. 27 Colinz Laboratories Limited Appoints Falguni Kumawat as Company Secretary and Compliance Officer, with Effect from 1 December, 2025 CI
Nov. 08 Colinz Laboratories Limited Announces of Demise Dr. Mani L.S., Founder Director, Company Secretary and Compliance Officer on 7 November 2025 CI
Nov. 03 Colinz Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
25-07-31 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
25-05-21 Colinz Laboratories Limited Appoints Swapnil Jayesh Madiyar as Additional Director, Effective from May 16, 2025 CI
25-05-16 Colinz Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
25-03-04 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
1 day-5.00%
1 week+2.65%
Current month-6.88%
1 month+31.57%
3 months+77.42%
6 months+49.62%
Current year+44.60%
1 week 77.55
Extreme 77.55
87.44
1 month 53.11
Extreme 53.11
87.44
Current year 39.31
Extreme 39.31
87.91
1 year 36.11
Extreme 36.11
87.91
3 years 33.35
Extreme 33.35
88.7
5 years 15.55
Extreme 15.55
88.7
10 years 4.8
Extreme 4.8
88.7
Manager TitleAgeSince
Chief Executive Officer 73 -
Director of Finance/CFO - 2019-05-19
Compliance Officer - 2025-11-30
Director TitleAgeSince
Director/Board Member 73 1990-11-25
Director/Board Member 33 2024-08-07
Director/Board Member 76 2024-08-07
Change 5-day change 1-year change 3-year change Capi.($)
-5.00%+2.65%+81.53%+120.44% 2.16M
+1.81%+2.25%+13.55%+81.13% 47.15B
-2.54%+4.24%+63.60%+114.38% 37.94B
+0.15%+1.26%-2.63%+43.67% 12.35B
+3.71%+3.56%+14.59%+95.63% 11.52B
+1.75%-1.34%+33.25%+122.84% 8.93B
+0.66%+0.41%+23.13%+44.77% 7.14B
+0.71%+3.35%+54.96%-7.18% 7.02B
+0.68%+2.63%+24.92%+227.07% 6.51B
+9.99%+27.85%-16.33%+28.50% 5.98B
Average +1.19%+4.43%+29.06%+87.13% 14.46B
Weighted average by Cap. +0.85%+3.27%+28.36%+88.70%

Financials

2024 2025
Net sales 70.3M 738K 645K 593K 553K 1.05M 1.06M 7.12M 2.77M 34.55M 2.77M 2.71M 119M 65.28M 686K 599K 551K 513K 974K 989K 6.61M 2.57M 32.09M 2.57M 2.52M 111M
Net income 4.87M 51.12K 44.69K 41.07K 38.28K 72.6K 73.7K 493K 192K 2.39M 192K 188K 8.24M 4.97M 52.16K 45.59K 41.9K 39.06K 74.08K 75.2K 503K 196K 2.44M 196K 192K 8.41M
Net Debt -64.3M -675K -590K -543K -506K -959K -974K -6.51M -2.53M -31.61M -2.53M -2.48M -109M -49.09M -516K -451K -414K -386K -732K -743K -4.97M -1.93M -24.13M -1.94M -1.89M -83.16M
Logo Colinz Laboratories Limited
Colinz Laboratories Ltd. is an India-based company that is engaged in the manufacturing and marketing of pharmaceutical formulations, particularly in the gynecological sector. It is engaged in the manufacturing and marketing various allopathic, ayurvedic, and nutraceuticals pharmaceutical formulations in the dosage forms of tablets, capsules, liquid orals and ointments, among others. The company has specialized products for Gynecology, cardiology, gastroenterology, and others. Its oncology products include imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, and doxorubicin. Its Ayurvedic products include anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, and memory boosters. Its nutraceuticals products include spirulina tabs/caps, spirulina with vitamins & minerals, omega 3 fatty acid caps in softgel, codliver oil with vitamin caps in soft gel, collagen, and glucosamine & chondroitin tabs.
Employees
65
Date Price Change Volume
26-07-03 77.55 -5.00% 465
26-07-02 ₹81.63 -4.99% 10,439
26-07-01 ₹85.92 +3.17% 83,999
26-06-30 ₹83.28 +4.99% 2,776
26-06-29 ₹79.32 +4.99% 6,381
  1. Stock Market
  2. Stocks
  3. COLINZ6 Stock